Palatin Technologies
About: Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Employees: 30
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
3,900% more call options, than puts
Call options by funds: $40K | Put options by funds: $1K
187% more capital invested
Capital invested by funds: $1.43M [Q3] → $4.1M (+$2.67M) [Q4]
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
10.61% more ownership
Funds ownership: 8.25% [Q3] → 18.86% (+10.61%) [Q4]
8% more funds holding
Funds holding: 36 [Q3] → 39 (+3) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
793%
upside
Avg. target
$7
793%
upside
High target
$7
793%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 75 / 411 met price target | 793%upside $7 | Buy Maintained | 13 Feb 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
3 weeks ago
Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript
Palatin Technologies, Inc. (NYSE:PTN ) Q2 2025 Earnings Conference Call February 13, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary Conference Call Participants Joe Pantginis - H. C. Wainwright Operator Greetings.
Neutral
PRNewsWire
4 weeks ago
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout expected later this month Novel 'next generation' selective MC4R long-acting peptide and an oral small molecule Multiple clinical trials targeted in calendar year 2025 For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesity Phase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarter Teleconference and Webcast to be held on February 13, 2025, at 11:00 AM ET CRANBURY, N.J. , Feb. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2024 and the completion of database lock for its Phase 2 obesity co-administration study with melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist tirzepatide.
Neutral
PRNewsWire
1 month ago
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
CRANBURY, N.J. , Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets.
Neutral
PRNewsWire
1 month ago
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
CRANBURY, N.J. , Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the "Registered Direct Offering") at a purchase price of $1.00 per share.
Neutral
PRNewsWire
1 month ago
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J. , Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP tirzepatide for the treatment of obesity.
Neutral
PRNewsWire
1 month ago
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Obesity programs: Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Topline results expected 1Q calendar year 2025 General obesity, weight loss management, and rare neuroendocrine and genetic diseases, including hypothalamic obesity Multiple clinical trials targeted to commence 2H calendar year 2025 with long-acting MC4R peptide and/or MC4R oral small molecule compounds Dry eye disease and other ocular programs, ulcerative colitis, and diabetic nephropathy programs: Program specific licensing/collaboration and spinout discussions ongoing with multiple deals targeted for calendar year 2025 CRANBURY, N.J. , Jan. 28, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system (MCRS), today provided an update on anticipated corporate milestones expected to occur in calendar year 2025.
Neutral
PRNewsWire
2 months ago
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy Demonstrated efficacy at 6 months 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr) 71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR) Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patients CRANBURY, N.J. , Dec. 19, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced topline data for the BREAKOUT study.
Neutral
PRNewsWire
2 months ago
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
CRANBURY, N.J. , Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant exercise inducement agreement (the "inducement agreement") with an institutional investor to exercise certain outstanding warrants that the Company issued in June 2024 and October 2023 totaling 3,907,679 shares of the Company's common stock for gross proceeds of approximately $3.4 million.
Neutral
PRNewsWire
3 months ago
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and tolerability concerns Preclinical data demonstrated that oral PL8177 caused diseased colons to move towards a healthy state and to resolve damaging inflammation Data expected 1Q calendar year 2025 CRANBURY, N.J. , Nov. 25, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of enrollment in its Phase 2 Study of PL8177, a potent melanocortin-1 receptor (MC1R) agonist, in ulcerative colitis (UC).
Neutral
Seeking Alpha
3 months ago
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
Palatin Technologies, Inc. (NYSE:PTN ) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary Conference Call Participants Joe Pantginis - H. C. Wainwright Operator Greetings.
Charts implemented using Lightweight Charts™